HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ICCVAM panel report

This article was originally published in The Rose Sheet

Executive Summary

National Toxicology Program Interagency Center on Evaluation of Alternative Toxicological Methods is requesting comments on a report by Interagency Coordinating Committee on the Validation of Alternative Methods scientific peer review panel regarding the 3T3 mouse fibroblast test and the normal human keratinocyte method, agency says in July 11 Federal Register notice. Report contains conclusions from May 23 meeting, including recommendation that the in vitro cytotoxicity test methods are sufficient for use in a weight-of-evidence approach to determine the starting dose for acute oral in vivo toxicity testing (1"The Rose Sheet" May 29, 2006, p. 8). Comments are due Aug. 25...

You may also be interested in...



ICCVAM Peer Review Meeting Evaluates Two In Vitro Cytotoxicity Tests

Two in vitro cytotoxicity test methods are sufficient for use in a weight-of-evidence approach to determine the starting dose for acute oral in vivo toxicity testing, a scientific peer review panel concluded by consensus during a meeting of the Interagency Coordinating Committee on the Validation of Alternative Methods in Bethesda, Md. May 23

Biogen Sees Improving Momentum In Slow Leqembi Launch

Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.

Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease

Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS014072

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel